Molecular profiling in precision medicine oncology
Crossref DOI link: https://doi.org/10.1038/s41591-019-0442-2
Published Online: 2019-04-29
Published Print: 2019-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Le Tourneau, Christophe http://orcid.org/0000-0001-9772-4686
Borcoman, Edith
Kamal, Maud
Text and Data Mining valid from 2019-04-29
Article History
First Online: 29 April 2019
Competing interests
: C.L.T. has received consultant fees from Merck Serono, Merck & Co., Bristol-Myers Squibb, Amgen, Novartis, GlaxoSmithKline and Roche.